Start biologic DMARDs early in juvenile idiopathic arthritis: study

Disease activity is lower after a year with aggressive combined therapy approach, say researchers

Early aggressive use of biological disease-modifying antirheumatic drugs (bDMARDs) is more effective for newly diagnosed polyarticular course juvenile idiopathic arthritis (JIA) than a delayed approach, researchers say.

Boy with sore hand

The authors of a single-centre study of 465 newly diagnosed, DMARD-naïve patients said the early addition of bDMARDS to conventional synthetic DMARDs (csDMARDs) appeared to reduce disease activity by six months.

The study examined the records of patients, aged from 12 months to 19